Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Trends in State White Bagging Legislation

Joseph Cantrell, JD  |  Issue: April 2022  |  March 22, 2022

White bagging may not be a familiar concept for some rheumatologists, especially those in large practices or at academic institutions. For small and independent practices, however, this policy of designating specific sources for drugs represents a significant threat to patient safety and the way practices function. White bagging has also emerged as a hot topic of discussion in many state capitols this legislative session. None of the bills have passed yet, but the ACR is monitoring legislation in more than 10 states and expects that some of those states may approve bills this year.

What Is White Bagging?

Mandatory white bagging policies require physicians to acquire provider-administered drugs through a preferred specialty pharmacy designated by a payer or pharmacy benefit manager (PBM). Often, these preferred pharmacies are under the same corporate umbrella as the PBM or payer. Mandatory white bagging policies effectively end the buy and bill system that has worked for providers and patients for years.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a buy and bill system, providers can purchase medications and administer them as needed to patients. By contrast, under a white bagging policy, a medication is ordered through a payer-preferred pharmacy for a specific patient and can only be used for that patient. If that patient is unable to receive the medication before it expires, the drug must be wasted; it cannot be used for another patient. White bagging also does not allow for last-minute adjustments by the provider. If, at the time of administration, less than the ordered amount of drug is needed, the excess must be wasted. If more is needed, the patient can’t receive an appropriate dose because there is no allowance for extra medication. One reason that the buy and bill system is so important to patient care is that it allows for adjustments right up to the moment of infusion. Buy and bill ensures that patient care is personalized and determined by the provider and not a payer or a PBM.

Additionally, white bagging raises serious issues related to safety and timeliness. White bagging relies on “just in time” delivery of medications to providers. Delivery systems have long been plagued by disruption issues, problems that have been exacerbated during the pandemic. Delivery delays increase the chances of mishandling and drug spoilage. They can also delay care, raising the risk of a patient having a flare or incurring irreversible damage.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

State Activity

White bagging is attracting a lot of attention in state legislatures this year, largely driven by state hospital associations, because hospitals are an early target of white bagging policies. Thus far, hospital associations have been good partners on this issue. We have worked with them and our other partners in several states to ensure that the language in introduced bills is inclusive of providers.

Page: 1 2 3 | Single Page
Share: 

Filed under:Legislation & AdvocacyPractice Support Tagged with:drug accesspharmacy benefit managers (PBMs)state legislationwhite bagging

Related Articles

    What to Expect in Healthcare Policy from the 2023 State Legislative Sessions

    February 21, 2023

    With 2023 state legislative sessions underway, early prevailing themes may forecast areas where we will see gains this year. Key issues include utilization management, copay accumulator bans, white bagging and pharmacy benefit manager reform.

    Florida Law Puts Drug Pricing by Pharmacy Benefit Managers Under a Microscope Once Again

    August 8, 2022

    As of July 1, a Florida bill increases oversight of pharmacy benefit managers and offers some protection for pharmacies. However, the legislation has limited effects on patients and providers, highlighting the need for additional reform.

    State Legislative Issues to Watch in 2022

    January 7, 2022

    States increasingly take the lead on issues critical to our members and the field of rheumatology, including copay accumulator bans, white bagging restrictions, prior authorization and drug pricing.

    A Unique Partnership Gives the ACR a Voice in Insurance Legislation Development

    March 20, 2023

    A recent meeting of the National Council of Insurance Legislators (NCOIL) featured discussions of many topics important to ACR members, including pharmacy benefit manager legislation, biomarker testing and transparency in the healthcare market.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences